Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 2;81(5):126.
doi: 10.1007/s00284-024-03658-0.

Development, Strategies, and Challenges for Tularemia Vaccine

Safoura Moradkasani  1   2 , Max Maurin  3 , Amir Salek Farrokhi  4 , Saber Esmaeili  5   6
Affiliations
Review

Development, Strategies, and Challenges for Tularemia Vaccine

Safoura Moradkasani et al. Curr Microbiol. .

Abstract

Francisella tularensis is a facultative intracellular bacterial pathogen that affects both humans and animals. It was developed into a biological warfare weapon as a result. In this article, the current status of tularemia vaccine development is presented. A live-attenuated vaccine that was designed over 50 years ago using the less virulent F. tularensis subspecies holarctica is the only prophylactic currently available, but it has not been approved for use in humans or animals. Other promising live, killed, and subunit vaccine candidates have recently been developed and tested in animal models. This study will investigate some possible vaccines and the challenges they face during development.

PubMed Disclaimer

References

    1. Flora S (2020) Biological warfare agents: history and modern-day relevance. Handbook on biological warfare preparedness. Elsevier, Amsterdam, pp 1–11. https://doi.org/10.1016/B978-0-12-812026-2.00001-3 - DOI
    1. Sunagar R et al (2016) Tularemia vaccine development: paralysis or progress? Vaccine (Auckl) 6:9–23. https://doi.org/10.2147/vdt.S85545 - DOI - PubMed
    1. Oyston PC, Quarry JE (2005) Tularemia vaccine: past, present and future. Antonie Van Leeuwenhoek 87(4):277–281. https://doi.org/10.1016/B978-0-12-812026-2.00001-3 - DOI - PubMed
    1. Maurin M et al (2024) Tularemia treatment: experimental and clinical data. Front Microbiol 14:1348323. https://doi.org/10.3389/fmicb.2023.1348323 - DOI - PubMed - PMC
    1. Maurin M, Gyuranecz M (2016) Tularaemia: clinical aspects in Europe. Lancet Infect Dis 16(1):113–124. https://doi.org/10.1016/S1473-3099(15)00355-2 - DOI - PubMed

LinkOut - more resources